@article {8213,
	title = {Neoadjuvant cisplatin and interferon-α2B in the treatment and organ preservation of penile carcinoma},
	journal = {Journal of Urology},
	volume = {152},
	year = {1994},
	note = {Cited By :16Export Date: 21 February 2017},
	month = {1994},
	pages = {1124 - 1126},
	abstract = {We investigated the antitumor activity and toxicity of cisplatin and interferon-α2B as the primary treatment of penile carcinoma. A total of 13 consecutive patients with nonmetastatic, histologically confirmed invasive squamous cell carcinoma of the penis underwent treatment consisting of 20 mg./m.2 cisplatin intravenously and 5 x 106 μ./m.2 interferon-α2B subcutaneously daily for 5 consecutive days. An equivalent dose of interferon was then administered subcutaneously every 2 days for 3 weeks and the regimen was repeated at 28-day intervals. Of 12 evaluable patients 9 responded: 4 achieved a pathologically confirmed complete remission of 38+, 21+, 10 and 7 months in duration (2 with relapse were treated with local therapy and remain with no evidence of disease), and 5 achieved a partial response, underwent surgical removal of residual disease and remained disease-free for 14+ to 24+ months. The most significant toxicities were anemia in 5 patients and reversible renal impairment in 3 but no patient had neutropenic fever or required platelet transfusion. We conclude that primary treatment with cisplatin and interferon-α2B induced responses in 75\% of 12 patients with penile carcinoma and allowed for a less radical operation than originally scheduled. A larger number of patients and longer followup will be required to confirm these encouraging preliminary results.},
	keywords = {Cisplatin, interferon alfa-2B, Interferon-alpha, penile neoplasms},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-0028168456\&partnerID=40\&md5=9d63ef51e32caf00d6ead9cc509be83a},
	author = {Mitropoulos, D. and Dimopoulos, M.-A. and Kiroudi-Voulgari, A. and Zervas, A. and Dimopoulos, C. and Logothetis, C. J.}
}
